Unichem Laboratories, a Rs.1,200 crore plus Mumbai based pharma major, has suffered minor setback during the second quarter ended September 2016 and its consolidated net profit declined by 11.3 per cent to Rs.20.52 crore from Rs.23.13 crore in the corresponding period of last year. However, its consolidated net sales increased by 19 per cent to Rs.361.04 crore from Rs.303.28 crore. With lower net profit, EPS declined to Rs.2.26 from Rs.2.55 in the last period.

Its domestic sales increased by 15.1 per cent to Rs.231.17 crore from Rs.200.79 crore and its international sales moved up by 25.6 per cent to Rs.136.87 crore from Rs.109 crore in the similar quarter of last year.

For the first half ended September 2016, Unichem's consolidated net sales increased by 15 per cent to Rs.695.94 crore from Rs.607.77 crore in the same half of last year. Its net profit declined by 11.2 per cent to Rs.46.29 crore from Rs.52.12 crore. Its cumulative filings of ANDAs stood at 37 of which 21 ANDAs are approved. Similarly, its cumulative filings of US DMFs stood at 48. Its API sales declined to Rs.45.3 crore from Rs.53.3 crore.

Its US subsidiary Unichem Pharmaceuticals USA Inc posted higher sales growth of 27 per cent during the first half to US$ 19.3 million as against $15.2 million in the similar period. Its net profit stood at $0.46 million.

Niche Generics Ltd, the 100 per cent UK subsidiary posted higher sales of Pound 5.5 million during the first half ended September 2016 as compared to Pound 4.1 million in the same period of last year. Its net profit stood at Pound 0.18 million.